ClinicalTrials.gg
Active, not recruitingNCT04211675STINGUpdated Sep 16, 2026

NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab

A Phase 1/2 interventional study of Natural Killer Cells and Temozolomide in Relapsed Neuroblastoma and Refractory Neuroblastoma, sponsored by Nationwide Children's Hospital. Active, not recruiting at 1 site in United States. Open to participants aged Up to 29 Years. Per ClinicalTrials.gov, last updated 2026-09-16.

Sponsored by Nationwide Children's Hospital · Phase 1/2, Interventional, and Treatment

How we know · 7 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
31
Allocation
Not applicable
Ages
Up to 29 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 26 studies testing temozolomide in Neuroblastoma — 7 open to participants now, 9 under way, 2 of them phase 3. Temozolomide · Neuroblastoma.

Planned enrollment
14th of 23
31 · median 41
Started
2022
with 1 other
Phase 1/2
5 of 26
1 open now
Registered
12th of 26
by date

Among the 26 studies testing temozolomide in Neuroblastoma, this one is the 14th largest by planned enrollment of the 23 interventional ones that give a count, is one of 2 that started in 2022, is one of 5 in phase 1/2, and was the 12th registered.

Neuroblastoma

676 studies on the registry are indexed under Neuroblastoma; 127 are open to participants now.

Browse Neuroblastoma studies →

Open to participants now

7 of the 26 studies testing temozolomide in Neuroblastoma are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About temozolomide

Temozolomide: first FDA approval 1999 (TEMODAR), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 104 Neuroblastoma studies recruiting now, 25 (24%) set no upper age limit and 74 (71%) stop at 75 or younger; 101 take children under 18; 3 take healthy volunteers.

This study: Up to 29 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing temozolomide in Neuroblastoma, or all of them as a file.
02

Study summary

This is a Phase 1 study with Phase 2 expansion cohort. Phase 1 will assess the safety and tolerability of universal donor TGFβi NK Cell in combination with irinotecan, temozolomide, and dinituximab. The phase 2 of the study will estimate the response to treatment.

03

Conditions studied

  • Relapsed Neuroblastoma
  • Refractory Neuroblastoma

Browse trials for

04

Who can participate

Ages eligible
Up to 29 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Less than 30 years of age when registered on the study.
  • Patients must have a histologic verification of neuroblastoma (NBL) or ganglioneuroblastoma or NBL cells in bone marrow with or without elevated urine catecholamines.
  • >2 months, AND one of the following:

    • Recurrent disease; or
    • First episode of progressive disease (new lesion, increase in size, previous negative bone marrow) during initial multi-drug, induction myelosuppressive therapy; or
    • Primary resistant/ disease (partial, mixed, stable response criteria met) after completing at least 4 cycles of induction multi-drug induction chemotherapy
  • One of the following:

    • Patients must have measurable or evaluable tumor defined as: a) Measurable tumor on MRI or CT obtained within 4 weeks prior to study entry; Measurable is defined as ≥ 10mm in at least one dimension AND that has positive uptake on I-123 MIBG scan ("MIBG avid") or demonstrates increased FDG uptake on 18F-FDG PET-CT or PET-MRI ("PET-avid"); OR b) Evaluable tumor by I-123 MIBG scan within 4 weeks prior to study entry, defined as positive uptake at a minimum of one site;
    • Measurable or evaluable disease must represent recurrent disease after therapy completion or progressive disease on therapy or refractory disease during induction;
    • Patients with refractory disease that are not avid on MIBG scan and do not have increased FDG uptake on PET must have proven viable NBL;
    • New soft tissue sites that are MIBG avid or PET avid do not require biopsy as long as initial -confirmed NBL diagnosis prior to current therapy
  • Patients must have progressed during or following completion of frontline therapy. Agents considered to be a part of frontline therapy would include chemotherapy, radiation therapy, stem cell transplantation, retinoids, immunotherapy with anti GD2 agents, cellular therapies, or I-131 MIBG, and frontline therapy is defined as any combination of these agents defined in published regimens or current cooperative group clinical trials for the successful treatment of that cancer. Therapy may not have been received more recently than the timeframes defined below:

    • Myelosuppressive chemotherapy: At least 14 days since completion of myelosuppressive therapy
    • Biologic: At least 7 days since completion of therapy with non-myelosuppressive biologic or retinoid
    • Radiation: At least 4 weeks since completion of radiation to any site identified as a target lesion. Palliative radiation is allowed to sites not used to measure response
    • Stem Cell Transplant (SCT): At least 6 weeks after autologous stem cell transplant or stem cell infusions as long as hematologic criteria have been met
    • 131I-MIBG Therapy: At least 6 weeks after therapeutic MIBG treatment
    • Cellular therapies: At least 6 weeks after any cellular therapy treatment (e.g., prior NK, CAR-T therapy)

Subjects who have previously received anti-GD2 monoclonal antibodies for biologic therapy or for tumor imaging are eligible.

Subjects who have received autologous marrow infusions or autologous stem cell infusions that were purged using monoclonal antibody linked to beads are eligible.

No treatment with irinotecan and/ or temozolomide within the last 6 months.

  • Adequate bone marrow function, defined as:

    • Peripheral (ANC) ≥500/microL. Patients must not have received long-acting myeloid growth factors (e.g., Neulasta) within 14 days or short-acting myeloid growth factors (e.g., Neupogen) within 7 days of study entry.
    • count ≥50,000/microL (transfusion independent for at least 1 week)
  • Adequate renal function defined as:

    • or estimated radioisotope ≥70 ml/min/1.73m2 or
    • Serum creatinine \< 2x (ULN) based on age/gender
  • Adequate liver function defined as:

    • Total \<1.5x ULN for age AND
    • (ALT) ≤5x ULN for age (or ≤225 U/L). For purpose of this study, the ULN for SGPT (ALT) is 45 U/L.
  • Adequate central nervous system function defined as:

    • Patients with seizure disorders may be enrolled if seizures are well controlled on anti-convulsants
    • CNS toxicity ≤ Grade 2
  • Adequate cardiac function defined as:

    • Shortening fraction of ≥ 27% by ECHO OR
    • ≥ 50% by ECHO or gated radionuclide study
  • Adequate pulmonary function defined as:

    • No evidence of dyspnea at rest, no exercise intolerance, no chronic oxygen requirement, and room air pulse oximetry > 94% if there is a clinical indication for pulse oximetry

Exclusion criteria

Exclusion Criteria:

  • Patients who are pregnant or breastfeeding
  • Patients with elevated catecholamines (>2x ) only.
  • Patients must not have received 0.5 mg/ kg/ day (prednisone equivalent) doses of systemic for at least 7 days prior to enrollment.
  • Patients must not have received inducer or inhibitor for at least 7 days prior to study enrollment.
  • Patients must not have been diagnosed with any other .
  • Patients must not have > Grade 2 diarrhea.
  • Patients must not have uncontrolled infection.
  • Patients with history of Grade 4 allergic reactions to anti-GD2 antibodies or reactions that required discontinuation of anti-GD2 therapy.
  • Patients with a significant illness that is not covered by the exclusion criteria or that is expected to interfere with the action of study agents or to increase the severity of the toxicities experienced from the study treatment.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
31 participants (estimated)

Study arms

  • Other
    Treatment

    The planned therapy will involve 6 cycles of 21 days each consisting of irinotecan, temozolomide, dinutuximab, sargramostim, and natural killer (NK) cells. Treatment cycles will be repeated every 21 days based upon disease response and toxicity criteria. Tumor response will be assessed after Cycles 2, 4 and 6. Patients who do not experience dose-limiting toxicities and achieve complete response, partial response or stable disease may continue to receive the assigned therapy.

    Biological: Natural Killer Cells · Drug: Temozolomide · Drug: Irinotecan · Drug: Dinutuximab · Drug: Sargramostim

Interventions

  • BiologicalTroculeucelStudies of TroculeucelTroculeucel pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    NK cells dose 1x 108 cells/ kg on day 8 of each cycle

  • Temozolomide 100mg/m2/dose PO or IV daily on Days 1-5; if given orally, must be at least one hour prior to Irinotecan. For patients whose body surface area is \<0.5m2, temozolomide dosing is based on body weight in (kg), at a dose of 3.3 mg/kg/dose.

    Also known as: Temodar

  • Irinotecan 50mg/m2/dose IV daily on Days 1-5

    Also known as: Camptosar

  • Dinutuximab 17.5mg/m2/dose IV daily on Days 2-5

  • Sargramostim 250mcg/m2/dose subcutaneous daily on Days 6-12

    Also known as: Leukine

06

What researchers measure

Primary outcomes

  1. NK cells safety and tolerability: Number of participants with treatment-related adverse events and toxicities

    Number of participants with treatment-related adverse events and toxicities as assessed by CTCAE v4.0

    Time frame: 12 months

  2. Response to NK Cell treatment as determine by CT/MRI imaging

    To estimate the response to treatment, as determined by disease status evaluated using CT/MRI scans through the measuring tool RECIST.

    Time frame: 24 months

  3. Response to NK Cell treatment as determine by MIBG scans imaging

    To estimate the response to treatment, as determined by disease status evaluated using MIBG scans through the Curie score system.

    Time frame: 24 months

  4. Response to NK Cell treatment as determine by bone marrow aspiration

    To estimate the response to treatment, as determined by disease status evaluated using bone marrow aspiration and biopsy through H\&E stain. RECIST.

    Time frame: 24 months

Secondary outcomes

  1. Toxicity Definition of NK cells

    Toxicity will be graded using the CTCAE criteria, version 5.0. All grade 3+ toxicities will be reviewed for attribution.

    Time frame: 36 months

Other outcomes

  1. Assessment of the phenotype of expanded NK cells for neuroblastoma patients

    NK cell phenotypes will be measured by mass cytometry (unit of measure= % of nucleated cells)

    Time frame: 36 months

  2. Assessment of function of expanded NK cells for neuroblastoma patients

    NK cell functional potency will be measured as cytotoxicity by calcien- AM cytotoxicity assays (unit of measure= % of patietns with complete response (CR), very good partial response (VGPR), partial response (PR), stable disease (SD), or progressive disease (PD) with calculated 95% confidence intervals)

    Time frame: 36 months

  3. In vivo persistence of NK cells after adoptive transfer.

    To assess in vivo persistence of expanded NK cells after adoptive transfer by assessing NK cell number and phenotype in peripheral blood using mass cytometry.

    Time frame: 36 months

  4. Correlation of persistence of NK cells after adoptive transfer with clinical outcomes

    Clinical outcomes will be assessed by disease response using CT/MRI scans, I-123 metaiodobenzylguanidine (MIBG) scans, and bone marrow aspiration and biopsy

    Time frame: 36 months

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2022 (actual). Primary completion is estimated for Dec 2026, 51 months after the start.

Of 35 phase 1/2 interventional studies under Neuroblastoma, half reached primary completion within 80 months of starting (the median), counting those still running; a quarter within 62 and three quarters within 115. This study's planned 51 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2019
First posted
Dec 26, 2019
StartActual
Sep 1, 2022
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2027
Last update
Sep 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04211675
Responsible party
Sponsor
First posted
Dec 26, 2019
Start date
Sep 1, 2022
Primary completion
Dec 2026 (estimated)
Completion
Dec 2027 (estimated)
Last update
Sep 16, 2026

Study contacts

Mark Ranalli, MD
principal investigator · Nationwide Children's Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Temozolomide · Irinotecan · Dinutuximab

Start the discussion